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Several studies have reported the efficacy and safety of polyphenols in human health; however, the verification of their efficacy
remains insufficient. The aim of this study was to examine whether fisetin, one of flavonoids prevalently present in fruits and
vegetables, could suppress lipopolysaccharide- (LPS-) induced inflammatory responses in macrophages. LPS increased
proinflammatory mRNA abundance (MCP 1, IL-1β, and iNOS) but were suppressed by fisetin. The increment of nitric oxide by
LPS, an oxidative stress factor, was attenuated by fisetin. In addition, LPS-enhanced phosphorylation of mitogen-activated
protein kinase (ERK and JNK) was reduced. Finally, fisetin attenuated the expression or activity of uPA, uPAR, MMP-2, and
MMP-9, which are known as associated factors of macrophage recruitment or infiltration. In conclusion, fisetin is a promising
therapeutic agent for macrophage-related inflammation diseases, like sepsis and atherosclerosis.
1. Introduction
The therapeutic usage of natural components has gained
more attention in the last 2 decades. Based on their great effi-
cacy and low toxicity, 40% of FDA-approved therapeutic
agents are natural-based components or their derivatives
[1]. Toxicity associated with other drugs has been success-
fully prevented by different natural products [2]. Thus, it is
very important and significant to explore plant-derived natu-
ral compounds further.
Polyphenols are the plant secondary metabolites and
widely present in foods and beverages of plant origin, fruits,
vegetables, spices, tea, and wine. Although they are not con-
sidered as essential micronutrients, several literatures evince
their beneficial effects on human health, especially in diets
associated with high consumption of fruits and vegetables
[3–5]. Numerous studies have been performed over decades
for investigation for pharmacological effects of polyphenols,
suggesting benefit for health. Growing evidence has shown
that a few polyphenols possess anti-inflammatory properties
[6–8]. In addition, recent studies have demonstrated that sev-
eral kinds of polyphenols can inhibit regulatory enzymes or
transcription factors which are involved in inflammation [9].
Diet influences different stages of inflammation and
demonstrates an important impact on several inflammatory
diseases [10, 11]. Inflammation plays a key role on the devel-
opment of diseases such as diabetes, asthma, cardiovascular
diseases, and cancer [12]. Therefore, controlling inflamma-
tion may prevent these diseases. Since macrophages are
major mediators of inflammation, they have diverse func-
tions in tissue homeostasis and inflammation. Thus, agents
effectively modulating their functions are of great clinical
value since aberrant activation of macrophages can cause
detrimental immune responses. Current research tendency
clearly indicates that natural products are one of the most
important sources of new drugs [13].
One polyphenol, fisetin (3,3′,4′,7-tetrahydroxyflavone),
is contained richly in strawberry, apple, tomato, onion,
orange, peach, grape, kiwi, persimmon, tea, and wine [14].
So far, fisetin has reported strong anti-inflammatory [15–17],
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antioxidant [18], antitumorigenic [19, 20], antiangiogenic
[21], antidiabetic [22], neuroprotective [23], and cardiopro-
tective effects [24] both in cell culture and in animal models
relevant to human diseases. Although fisetin has many phys-
iological effects, its effect on macrophages is not much
reported.
In the present study, we investigated the beneficial effects
of fisetin on the inflammatory response of macrophages acti-
vated by lipopolysaccharide (LPS).
2. Materials and Methods
2.1. Isolation of Resident Peritoneal Macrophages. BALB/c
mice were obtained from the Institute of Medical Science of
the University of Tokyo and maintained in the Animal
Resource Center of Okayama University. All the animal
experiments were performed to conform to the NIH guide-
lines (Guide for the Care and Use of Laboratory Animals).
The experimental protocol was approved by the Ethics
Review Committees for Animal Experimentation of Oka-
yama University Graduate School of Medicine, Dentistry,
and Pharmaceutical Sciences (OKU-2018449). All mice were
maintained in a barrier facility and fed a normal laboratory
diet. Male and female BALB/c mice, 16 ± 4weeks of age were
anesthetized with isoflurane and euthanized via cervical dis-
location. Macrophages were harvested via peritoneal lavage
using saline (5mL). The peritoneal lavage solution was cen-
trifuged at 1500 rpm for 5 minutes. The sediment was sus-
pended in a little DMEM (SIGMA, Cat. No. D6046). Red
blood cells were lysed using a solution of ammonium chlo-
ride. The number of macrophages were calculated using a
hemocytometer, then resuspended in DMEM containing
heat-inactivated FBS (10% v/v), penicillin (10U/mL), and
streptomycin (10mg/mL), and plated into 6-well plates
(Corning Incorporated, Cat. No. 3516) [25, 26].
2.2. Cell Culture Conditions. After overnight serum starva-
tion, macrophages were incubated with selected concentra-
tions of fisetin (10, 30, and 100μM; SIGMA, Cat. No.
F4043) or vehicle for 3 hours and incubated in the presence
or absence of LPS (10 ng/mL; SIGMA, Cat. No. L4391) for
an appropriate time. Then, the medium and cells were col-
lected. The medium was used for the nitric oxide (NO) assay
and gelatin zymography. Cell lysates were used for quantita-
tive polymerase chain reaction (qPCR) and western blotting.
2.3. Real-Time Polymerase Chain Reaction. mRNAs were
extracted from macrophages using RNeasy Mini Kits (QIA-
GEN, Cat. No. 74104). Reverse transcription was performed
using an iScript cDNA Synthesis Kit (Bio-Rad, Cat. No.
1708891). qPCR was performed with an ABI Step One
Real-Time PCR System (Applied Biosystems, QuantStudio
3) using a Fast SYBR Green Real-time PCRMixture (Applied
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Figure 1: Effects of fisetin on the expression of inflammatory mediators in macrophages stimulated with LPS. (a) mRNA expression of MCP-
1, IL-1β, and iNOS in LPS- (10 ng/mL) stimulated macrophages in the presence or absence of fisetin (10-100μM) by qPCR (n = 6 in each
group). Each bar presents the mean + SE of six experiments. ∗p < 0:05 vs. control group; #p < 0:05 vs. LPS-stimulated group. (b) NO
concentration in each cell culture supernatants by colorimetric assay (n = 3 in each group). Each bar presents the mean + SE of three
experiments. ∗p < 0:05 vs. control; #p < 0:05 vs. LPS.
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chemotactic protein 1 (MCP-1) (Takara Bio Inc., Cat. No.
MA066003), interleukin 1 beta (IL-1β) (Takara Bio Inc.,
Cat. No. MA025939), inducible nitric oxide synthase (iNOS)
(Takara Bio Inc., Cat. No. MA083369), matrix metallopro-
teinase- (MMP-) 2 (Takara Bio Inc., Cat. No. MA127110),
MMP-9 (Takara Bio Inc., Cat. No. MA031311), and 18S ribo-
somal RNA (18S) (Takara Bio Inc., Cat. No. MA050364)
were commercially available. Each sample was normalized
to values for 18S mRNA expression (ΔΔCT method) [27].
2.4. Nitric Oxide Assay. The individual cell culture superna-
tants were collected and centrifuged 10min at 14,000 rpm
at 4°C. Then, the supernatant was used for nitric oxide
(NO) assay. The NO assay was performed as described in
the commercially available kits (BioAssay Systems, Cat. No.
D2NO-100). BioAssay Systems’ QuantiChrom™ Nitric
Oxide Assay Kit is a colorimetric assay for the determination
of NO production following reduction of nitrate to nitrite
using the improved Griess method.
2.5. Western Blotting. Whole cell proteins were extracted
from macrophages using a lysis buffer (Cell Signaling, Cat.
No. 9803). Each sample was applied into 10% SDS-PAGE
and transferred to a polyvinylidene fluoride membrane,
immunoblotted with primary antibodies (the phosphoryla-
tion of extracellular signal-regulated kinase (p-ERK); Cell
Signaling, Cat. No. 9101, the phosphorylation of c-Jun N-
terminal kinase (p-JNK); Cell Signaling, Cat. No. 9251, the
urokinase plasminogen activator (uPA); Abcam, Cat. No.
ab20789, the urokinase plasminogen activator and receptor
(uPAR); R&D, Cat. No. AF534, and β-actin; Sigma Cat. No.
A5441) [28]. Membranes were then incubated with appropri-
ate secondary antibodies, and immune complexes were visual-
ized on chemiluminescence (Merck Millipore, Cat. no.
WBLUF0100, Cat. no. WBLUC0100) and quantified using a
General Electric Imager (GE Healthcare, LAS 4000 mini) [29].
2.6. Gelatin Zymography. Cell culture supernatants were
resolved under nonreducing conditions by SDS-PAGE
(10% wt/vol) polymerized in the presence of gelatin (0.1%
wt/wt) to evaluate the activities of MMP-9. Gels were washed
with Triton X-100 (2.5% vol/vol) for 60min and distilled
water for 15min two times. Gels were then incubated over-
night at 37°C in 50mM Tris buffer containing calcium chlo-
ride (5mM) pH8.0. After incubation, gels were stained with
Coomassie Brilliant Blue R-250 (Bio-Rad, Cat. No. 161-0436)
for 30min at room temperature, then followed by destaining
with Coomassie Brilliant Blue R-250 Destaining Solution
(Bio-Rad, Cat. No. 161-0438) until clear bands appeared.
Gel images were quantified using a General Electric Imager
(GE Healthcare, LAS 4000 mini); the unstained, translucent
digested regions represented areas of MMP activity [30].
2.7. Statistics. All statistical analyses were performed using
Sigma Plot v14.0 (Systat Software Inc., California, USA).
Data are presented as the mean ± standard error of the
mean. Statistical significance between multiple groups was
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Figure 2: Effects of fisetin on the protein expression of MAPKs in macrophages stimulated with LPS. (a) Protein expression of MAPK in LPS-
(10 ng/mL) stimulated macrophages for 0-60-minute incubation (n = 3 in each group). (b) Protein expression of MAPK in LPS- (10 ng/mL)
stimulated macrophages in the presence or absence of fisetin (100 μM) by western blotting (n = 3 in each group). (c) The relative expression of
each protein was quantified by densitometry and normalized to the band under the control condition. Each bar presents the mean + SE of
three experiments. ∗p < 0:05.
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by Holm-Sidak post hoc test or Student-Newman-Keuls post
hoc test. p value < 0.05 was considered statistically significant.
3. Results
3.1. Fisetin Attenuated Inflammatory Mediators in
Macrophages Stimulated with LPS. Since activated macro-
phages produce proinflammatory cytokines and inflamma-
tory mediators such as NO [8], we examined the effects of
fisetin on inflammatory mediators in macrophages stimulated
with LPS. First, to study whether fisetin exerts the anti-
inflammatory effect at the transcriptional level, we determined
mRNA expression levels of inflammatory genes such as MCP-
1, IL-1β, and iNOS (Figure 1(a)). As expected, the expressions
of these inflammatory genes were suppressed by fisetin in a
dose-dependent manner. Next, to confirm whether fisetin
suppresses inflammatory response in macrophages, we evalu-
ated its capability to suppress NO production in LPS-treated
macrophages (Figure 1(b)). As expected, fisetin decreased pro-
duction of NO in a dose-dependent manner.
3.2. Fisetin Reduced Mitogen-Activated Protein Kinase in
Macrophages Stimulated with LPS. Since fisetin was reported
to inhibit mitogen-activated protein kinase (MAPK) path-
ways in various cell types [31, 32], we examined the effects
of fisetin on MAPKs in macrophages. First, activation of
MAPKs induced by LPS in macrophages was observed
(Figure 2(a)). The increase in p-ERK by LPS peaked at 15
minutes after stimulation, while the increment of p-JNK by
LPS peaked at 30 minutes. Thus, in the subsequent experi-
ments, macrophages were stimulated with LPS for 30 minutes.
Cotreatment with fisetin significantly decreased LPS-induced
enhancement of p-ERK and p-JNK (Figures 2(b) and 2(c)).
3.3. Fisetin Reduced uPA and uPAR in Macrophages
Stimulated with LPS.Macrophage activation is closely corre-
lated to the invasiveness of cells. In addition, uPA and uPAR
in macrophages contribute to the infiltration of cells. Thus,
the effect of fisetin on the expression of uPA and uPAR was
investigated. LPS induced the protein abundance of uPA
(Figure 3(a)) and uPAR (Figure 3(b)). Cotreatment of fisetin
reduced the increment of uPA (Figure 3(a)) and uPAR by
LPS (Figure 3(b)).
3.4. Fisetin Reduced MMP-2 and MMP-9 in Macrophages
Stimulated with LPS. Furthermore, to elucidate effect of fise-
tin on MMPs, we examined MMP-2 and MMP-9 expres-
sions, the downstream mediators of uPA/uPAR. Regarding
the mRNA level, LPS significantly increased MMP-2 and
MMP-9 mRNA expression, compared with the vehicle treat-
ment (Figure 4(a)). Fisetin reduced the enhancement of these
gene expressions of MMP-2 or MMP9 induced by LPS in a
dose-dependent manner (Figure 4(a)). Moreover, the protein
activities of MMP-9 were evaluated by zymography
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Figure 3: Effects of fisetin on the protein expression of uPA and uPAR in macrophages stimulated with LPS. (a) Protein expression of uPA in
LPS- (10 ng/mL) stimulated macrophages in the presence or absence of fisetin (100 μM) by western blotting. The relative expression of each
protein was quantified by densitometry and normalized to the band under the control condition (n = 3 in each group). Each bar presents the
mean + SE of three experiments. ∗p < 0:05. (b) Protein expression of uPAR in LPS- (10 ng/mL) stimulated macrophages in the presence or
absence of fisetin (100 μM) by western blotting. The relative expression of each protein was quantified by densitometry and normalized to
the band under the control condition (n = 3 in each group). Each bar presents the mean + SE of three experiments. ∗p < 0:05.
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(Figure 4(b)). The protein activities of MMP-9 (92 kDa) were
increased by LPS stimulation, which was reduced by fisetin
(Figure 4(b)).
4. Discussion
We found an important effect of fisetin against inflammation
in macrophages. The present study demonstrated that fisetin
attenuated the induction of inflammatory components such
as MCP-1, IL-1β, iNOS, and NO, induced by LPS in macro-
phages. In addition, fisetin suppressed the activation of
MAPK and attenuated the LPS-induced increment of uPA
and uPAR expression. Moreover, fisetin attenuated the
increase of mRNA abundance of MMP-2 and MMP-9 and
the activity of MMP-9.
In sepsis caused by gram-negative infection, LPS is com-
monly recognized as the causative agent of sepsis. In many
studies, LPS has been used as a model of sepsis as well as an
inflammation. Moreover, chronic inflammation induces early
cancer by activation of inflammatory cells and improper pro-
duction of a preinflammatory mediator like iNOS and tran-
scription factors like the nuclear transcription factor kappa B
(NF-κB) [33]. Besides, it has also been reported that oxidative
stress is reduced by attenuating the expression of iNOS [34].
Our study demonstrated that fisetin may be effective in the
prevention and treatment of sepsis and septic shock, due to
the suppressive effect on mRNA abundance of proinflamma-
tory genes and the production of NO. In this study, fisetin sup-
pressed NO production by reducing the expression of mRNA
of the proinflammatory gene (iNOS); therefore, it was likely
that fisetin attenuated the oxidative stress. Consequently, these
results supported the anti-inflammatory, antitumorigenic, and
antioxidant effects of fisetin.
Several studies have reported that LPS induced the phos-
phorylation of MAPKs, including ERK and JNK [35]. In
addition, it has been reported that fisetin inhibits migration
and invasion of human cervical cells by downregulating
uPA expression through suppressing MAPK [36]. In macro-
phages, few reports are available regarding the effect of fisetin
on the expression and activity of uPA and uPAR. Our study
demonstrated for the first time that fisetin suppressed the
expression of uPA and uPAR induced by LPS through
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Figure 4: Effects of fisetin on MMP-2 and MMP-9 in macrophages stimulated with LPS. (a) mRNA expression of MMP-2 and MMP-9 in
LPS- (10 ng/mL) stimulated macrophages in the presence or absence of fisetin (10-100μM) by qPCR (n = 6 in each group). Each bar
presents the mean + SE of six experiments. ∗p < 0:05 vs. control group; #p < 0:05 vs. LPS-stimulated group. (b) The activation of MMP-9
in LPS- (10 ng/mL) stimulated macrophages in the presence or absence of fisetin (10-100μM) by gelatin zymography. The relative
expression of MMP-9 activity was quantified by densitometry and normalized to the band under the control condition (n = 3 in each
group). Each bar presents the mean + SE of three experiments. ∗p < 0:05.
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suppressing MAPK signaling in macrophages, as previously
reported in cancer cells.
MMPs are a family of proteases whose expression is
related to certain processes, such as development, physiology,
and pathology. In common, MMP-9 has been recognized as a
marker of various inflammatory diseases, such as atheroscle-
rosis, arthritis, and systemic lupus erythematosus [37]. In
addition, MMP-9 was closely associated with cell migration
[38, 39]. Several studies have particularly reported that
MMP-2 and MMP-9 are involved in atherogenesis and play
an important role in the stabilization of atherosclerotic pla-
ques [40–42]. On this point, our results suggest that inhibitors
of MMP-9 can offer promise as a therapeutic approach for the
stabilization of vulnerable plaques. Moreover, recent investiga-
tions have demonstrated that wound healing in the skin is
impaired by excessive activation of MMP-9 [43]. Therefore,
it was suggested that fisetin also has potential as a therapeutic
approach for healing in the skin. Future studies will be
required to elucidate its detail on molecular mechanism.
A recent trend in the pharmaceutical industry is discov-
ering strategies to develop the natural plant itself as the new
drug. Indeed, two recent animal studies have demonstrated
that LPS-induced acute pulmonary inflammation and
collagen-induced arthritis were improved by fisetin treat-
ment [32, 44]. Another ex vivo study also demonstrated that
fisetin was able to attenuate LPS-induced cytokine release
from leukocytes of patients with chronic obstructive pulmo-
nary disease or type 2 diabetes [45]. Many immunosuppres-
sive drugs have been developed to attenuate inflammatory
and autoimmune diseases [46–50]; nevertheless, most com-
pounds exhibit significant side effects. Since polyphenols are
commonly present in dietary fruits and vegetables, they pre-
sumably may be safer immunosuppressive agents [51, 52].
Fruits and vegetables contain a wide array of phytochemicals
including sesquiterpene lactones, terpenoids, polysaccharides,
and phenolic compounds. Our results, demonstrating the
anti-inflammatory, antitumorigenic, and antioxidant effects
of fisetin, strongly indicate that it can be developed as a new
drug. Although fisetin is a promising candidate for immuno-
therapy, the potential of natural products containing fisetin
as a therapeutic agent for a certain disease needs to be further
verified in the clinical setting.
5. Conclusions
The present study demonstrated that fisetin attenuated the
increments of inflammatory genes (MCP-1, IL-1b, and
iNOS), the production of NO, and the phosphorylation of
MAPK, uPA, uPAR, and MMPs, induced by LPS in macro-
phages. These results suggested that fisetin may be a thera-
peutic agent for several macrophage-related diseases.
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